BroadOak Partners acted as the exclusive placement agent for OpGen's growth capital round to accelerate the commercial momentum and further invest in the company's whole-genome analysis products and services. The $17 million round included new and existing investors.
Quanta Biosciences closes strategic transaction
BroadOak Partners provided financial advisory services to Quanta Biosciences. Quanta Biosciences develops leading qPCR reagents that enable sophisticated applications in life science and drug discovery laboratories throughout the world.
BroadOak Capital Partners, through its affiliate the BroadOak Fund, provided growth capital to AVANZA Laboratories, LLC in order to expand its services offering.
BroadOak Partners advises Orion Genomics, LLC, a privately held biotechnology company developing epigenetic research tools and molecular diagnostic products, on the non-exclusive license of the Company’s MethylScreen technology for research use in QIAGEN’s EpiTect Methyl qPCR Array System reagent kits.
We are pleased to announce that Kyle Wilson has joined BroadOak Capital Partners. As a new Partner, Kyle will build on his 13 years of investment banking experience and continue to provide superior M&A and capital formation advice to life sciences companies. Prior to BroadOak, Kyle was a Principal at Canaccord Genuity where he led the tools and diagnostics team and completed over $1.4 billion in life sciences transactions. Kyle was also a Vice President at RBC Capital markets where he successfully executed over $700 million in transactions. Kyle holds a B.S. in Business Administration, a Juris Doctorate and M.B.A., all from the University of Oklahoma.
With the addition of Kyle’s expertise and experience, BroadOak is even better positioned to provide its life sciences clients with access to deep domain expertise combined with transactional excellence. We welcome Kyle to the firm.
BroadOak Partners advises Cayman Chemical Company, Inc. on the replacement and expansion of its debt facilities and, through its affiliate the BroadOak Fund, was lead investor for the mezzanine tranche.
BroadOak Partners advises Albany Molecular Research, Inc., a leading contract manufacturer, on the acquisition of Hyaluron, Inc., a provider of cGMP manufacturing and sterile fill capabilities.
BroadOak Partners advises Molecular Transfer, Inc., a leading producer of transfection and transformation reagents, on the acquisition of GlobalStem, Inc., a provider of high-quality standardized tools and reagents used in stem cell research.